查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1362917

癌症切片检查市场规模、份额、趋势分析报告：按类型、用途、按产品、地区和细分市场预测，2023-2030

Cancer Biopsy Market Size, Share & Trends Analysis Report By Type (Liquid Biopsy, Core Needle Biopsy), By Application (Breast Cancer, Lung Cancer), By Product (Kits & Consumables, Instruments), By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 140 Pages | 商品交期: 2-10个工作天内

价格

癌症切片检查市场的成长和趋势：

Grand View Research, Inc.最新报告显示，到2030年，全球癌症切片检查市场规模预计将达到516.1亿美元，复合年复合成长率为8.04%。

分子医学的进步促进了癌症分子表征新仪器的创建。因此，液体活检的接受度和核准不断提高预计将成为整体市场成长的主要动力。

许多新兴製造商致力于开发可以改进基于内视镜检查的癌症切片检查的设备。例如，2023年3月，瑞典公司BiBBInstruments AB以EndoDrill品牌在癌症切片检查设备市场站稳了脚步。结合现有的切片检查仪器，该公司对其切片检查仪器进行了改进，以便能够快速、准确地诊断癌症患者。此外，我们还提供与空心针和软式内视镜切片检查相容的切片检查仪器。开拓这些新兴市场的公司预计将增加癌症切片检查设备的可及性。

随着液体活检的出现，基于肿瘤学的基因组资料分析和个人化医疗领域预计将显示出良好的前景。由于液体活检提供的巨大潜力，法规机构正在积极支持这些产品的商业化并促进其在临床实践中的使用。液体活检有助于透过各种体液检测癌症，并且该技术的进步使其成为获取用于诊断目的的癌症生物材料的有吸引力的非侵入性方法。

由于生物製药製造和基因组资料分析公司的大量投资和战略努力，液体活检领域预计将在未来年度迅速扩张。新兴企业表现出强烈的偏好与现有产业参与者建立合作关係，例如 QIAGEN Bioinformatics、Fabric Genomics、Agilent Technologies 和 SOPHiA Genetics。这种合作研究趋势预计将进一步推动整体市场成长。

癌症切片检查市场报告亮点

  • 到 2022 年，套件和消耗品将占据最大的按产品市场占有率，预计这种主导地位将在整个预测期内持续下去。从肿瘤切片检查到液体切片检查的重大转变推动了试剂盒和消耗品的广泛采用。
  • 组织切片检查仍然是切片检查过程的基石，并广泛用于各种诊断用途。此外，肿瘤切片检查主要用于个体层面的诊断和监测正在进行的肿瘤治疗的有效性。
  • 从用途来看，乳癌将在 2022 年主导全球市场，并预计在预测期内保持领先地位。开放式手术切片检查仍然是评估可疑乳房病变患者的标准，因为它在诊断此类病理具有明确的准确性。因此，该部门的收益因其在诊断乳房病变方面已被证实的有效性而得到加强。
  • 由于活跃组织和癌症基金会的集中，北美在 2022 年占据了最大的收益占有率。美国政府组织和私人癌症基金会的强大网络对该地区的产生收入能力做出了重大贡献。
  • 主要市场参与企业包括 QIAGEN、ANGLE plc、Myriad Genetics、Danaher、F. Hoffmann-La Roche Ltd.、Lucence Diagnostics Pte. Ltd.、GRAIL, Inc.、Guardant Health 和 BIOCEPT, INC.。

目录

第1章癌症切片检查市场：调查方法和范围

第2章癌症切片检查市场：执行摘要

  • 市场预测
  • 产品和类型简介
  • 应用程式简介
  • 竞争形势概览

第3章癌症切片检查市场：市场变数、趋势、范围

  • 市场体系预测
  • 市场动态
  • 产业分析工具

第4章癌症切片检查市场：产品业务分析

  • 癌症切片检查市场：产品波动分析
  • 装置
  • 套件和消耗品
  • 服务

第5章癌症切片检查市场：类型业务分析

  • 癌症切片检查市场：类型变异分析
  • 组织切片检查
  • 液体活检
  • 其他的

第6章癌症切片检查市场：用途业务分析

  • 癌症切片检查市场：用途变化分析
  • 乳癌
  • 大肠直肠癌
  • 子宫颈癌
  • 肺癌
  • 摄护腺癌
  • 皮肤癌
  • 血癌
  • 肾癌
  • 肝癌
  • 胰臟癌
  • 卵巢癌
  • 其他的

第7章癌症切片检查市场：区域业务分析

  • 区域市场简介
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东/非洲

第8章癌症切片检查市场：竞争形势

  • 公司分类
  • 策略规划
  • 2022 年公司市场占有率分析
  • 公司简介

第9章KOL推荐/分析师观点

Product Code: GVR-4-68039-254-2

Cancer Biopsy Market Growth & Trends:

The global cancer biopsy market size is estimated to reach USD 51.61 billion by 2030, and is projected to expand at a CAGR of 8.04%, according to a new report by Grand View Research, Inc.. The advancement in molecular medicine has facilitated the creation of novel devices for the molecular characterization of cancers. As a result, the rising acceptance and approvals of liquid biopsies are anticipated to be significant driving forces behind the overall market growth.

Numerous emerging manufacturers are dedicated to developing instruments that can improve endoscopy-based cancer biopsies. For instance, in March 2023, BiBBInstruments AB, a Swedish company, established a strong presence in the cancer biopsy instruments market under the brand - EndoDrill. The company changed biopsy instruments that allow rapid and precise diagnosis of cancer patients related to existing biopsy instruments. Moreover, it offers biopsy instruments catering to core needles and flexible endoscopic biopsies. Such companies developing in the market are expected to upsurge the accessibility of cancer biopsy instruments.

The field of oncology-based genomic data analysis and personalized medicine is anticipated to witness lucrative prospects with the emergence of liquid biopsies. Regulatory bodies are actively backing the commercialization of these products and promoting their utilization in clinical settings due to the significant potential they offer. Liquid biopsy facilitates cancer detection through various body fluids, and the advancements in this technique have made it an appealing noninvasive approach for obtaining cancer biomaterials for diagnostic purposes.

The liquid biopsies segment is projected to experience rapid expansion in the upcoming years, driven by significant investments and strategic efforts from companies engaged in biopharmaceutical manufacturing and genomic data analysis. Emerging companies are showing a strong inclination towards forming partnerships with established industry participants like QIAGEN Bioinformatics, Fabric Genomics, Agilent Technologies, and SOPHiA Genetics. This collaborative trend is expected to further boost the overall market growth.

Cancer Biopsy Market Report Highlights:

  • In 2022, kits and consumables held the largest market share by product, and this dominance is projected to persist throughout the forecast period. The increased adoption of kits and consumables can be attributed to the notable shift from tumor biopsies to liquid biopsies
  • Tissue biopsies remain a fundamental aspect of the biopsy process and are widely utilized across various diagnostic applications. Furthermore, tumor biopsies are primarily employed for individual-level diagnosis and monitoring the efficacy of ongoing oncology treatments
  • In terms of application, breast cancer dominated the global market in 2022 and is expected to maintain its lead throughout the forecast period. Open surgical biopsy remains a reference standard for evaluating patients with suspicious breast lesions, owing to its established accuracy in diagnosing such conditions. Consequently, this segment's revenue is bolstered by its proven efficacy in breast lesion diagnosis
  • North America held the largest revenue share in 2022 owing to the concentrated pool of active organizations and cancer foundations. The strong network of government organizations and private cancer foundations in the U.S. has made significant contributions to the regional revenue generation capacity
  • Some of the key market participants are QIAGEN, ANGLE plc, Myriad Genetics, Danaher, F. Hoffmann-La Roche Ltd., Lucence Diagnostics Pte. Ltd., GRAIL, Inc., Guardant Health, and BIOCEPT, INC. among others

Table of Contents

Chapter 1 Cancer Biopsy Market: Research Methodology And Scope

  • 1.1 Market Segmentation and Scope
    • 1.1.1 Segment Definitions
      • 1.1.1.1 Product Segment
      • 1.1.1.2 Type Segment
      • 1.1.1.3 Application Segment
      • 1.1.1.4 End Use Segment
  • 1.2 Regional Scope
  • 1.3 Estimates And Forecast Timeline
  • 1.4 Objectives
    • 1.4.1 Objective - 1
    • 1.4.2 Objective - 2
    • 1.4.3 Objective - 3
  • 1.5 Research Methodology
  • 1.6 Information Procurement
    • 1.6.1 Purchased Database
    • 1.6.2 Gvr's Internal Database
    • 1.6.3 Secondary Sources
    • 1.6.4 Primary Research
  • 1.7 Information Or Data Analysis
    • 1.7.1 Data Analysis Models
  • 1.8 Market Formulation & Validation
  • 1.9 Model Details
    • 1.9.1 Commodity Flow Analysis
  • 1.10 List Of Secondary Sources
  • 1.11 List Of Abbreviations

Chapter 2 Cancer Biopsy Market: Executive Summary

  • 2.1 Market Outlook
  • 2.2 Product And Type Snapshot
  • 2.3 Application Snapshot
  • 2.4 Competitive Landscape Snapshot

Chapter 3 Cancer Biopsy Market: Market Variables, Trends & Scope

  • 3.1 Market Lineage Outlook
    • 3.1.1 Related/Ancillary Market Outlook
  • 3.2 Market Dynamics
    • 3.2.1 Market Drivers Analysis
      • 3.2.1.1 Advent Of Liquid Biopsy
      • 3.2.1.2 Transition Of Novel Oncology Diagnostics From Bench To Clinics
      • 3.2.1.3 Advancements In Quality And Payment Pertaining To Genetic Cancer Tests
    • 3.2.2 Market Restraint Analysis
      • 3.2.2.1 Risks Associated With Biopsy Procedures
      • 3.2.2.2 Technical And Clinical Challenges
  • 3.3 Industry Analysis Tools
    • 3.3.1 Porter's Analysis
    • 3.3.2 Pestel Analysis

Chapter 4 Cancer Biopsy Market: Product Business Analysis

  • 4.1 Cancer Biopsy Market: Product Movement Analysis
  • 4.2 Instruments
    • 4.2.1 Instruments Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 4.3 Kits And Consumabkes
    • 4.3.1 Kits And Consumabels Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 4.4 Services
    • 4.4.1 Services Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 5 Cancer Biopsy Market: Type Business Analysis

  • 5.1 Cancer Biopsy Market: Type Movement Analysis
  • 5.2 Tissue Biopsies
    • 5.2.1 Tissue Biopsies Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 5.2.2 Needle Biopsies
      • 5.2.2.1 Needle Biopsies Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 5.2.2.2 Fine Needle Aspiration (Fna)
      • 5.2.2.2.1 Fine Needle Aspiration (Fna) Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 5.2.2.3 Core Needle Biopsy (Cnb)
      • 5.2.2.3.1 Core Needle Biopsy (Cnb) Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 5.2.3 Surgical Biopsies
      • 5.2.3.1 Surgical Biopsies Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.3 Liquid Biopsies
    • 5.3.1 Liquid Biopsies Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.4 Others
    • 5.4.1 Others Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 6 Cancer Biopsy Market: Application Business Analysis

  • 6.1 Cancer Biopsy Market: Application Movement Analysis
  • 6.2 Breast Cancer
    • 6.2.1 Breast Cancer Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.3 Colorectal Cancer
    • 6.3.1 Colorectal Cancer Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.4 Cervical Cancers
    • 6.4.1 Cervical Cancers Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.5 Lung Cancers
    • 6.5.1 Lung Cancers Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.6 Prostate Cancers
    • 6.6.1 Prostate Cancers Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.7 Skin Cancers
    • 6.7.1 Skin Cancers Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.8 Blood Cancers
    • 6.8.1 Blood Cancers Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.9 Kidney Cancers
    • 6.9.1 Kidney Cancers Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.10 Liver Cancers
    • 6.10.1 Liver Cancers Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.11 Pancreatic Cancers
    • 6.11.1 Pancreatic Cancers Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.12 Ovarian Cancers
    • 6.12.1 Ovarian Cancers Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.13 Others
    • 6.13.1 Others Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 7 Cancer Biopsy Market: Regional Business Analysis

  • 7.1 Regional Market Snapshot
  • 7.2 North America
    • 7.2.1 North America Cancer Biopsy Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.2.2 U.S.
      • 7.2.2.1 U.S. Cancer Biopsy Market, 2018 - 2030 (USD Million)
      • 7.2.2.2 Key Country Dynamics
      • 7.2.2.3 Regulatory Framework
      • 7.2.2.4 Reimbursement Scenario
    • 7.2.3 Canada
      • 7.2.3.1 Canada Cancer Biopsy Market, 2018 - 2030 (USD Million)
      • 7.2.3.2 Key Country Dynamics
      • 7.2.3.3 Regulatory Framework
      • 7.2.3.4 Reimbursement Scenario
  • 7.3 Europe
    • 7.3.1 Europe Cancer Biopsy Market, 2018 - 2030 (USD Million)
    • 7.3.2 Uk
      • 7.3.2.1 Uk Cancer Biopsy Market, 2018 - 2030 (USD Million)
      • 7.3.2.2 Key Country Dynamics
      • 7.3.2.3 Regulatory Framework
      • 7.3.2.4 Reimbursement Scenario
    • 7.3.3 Germany
      • 7.3.3.1 Germany Cancer Biopsy Market, 2018 - 2030 (USD Million)
      • 7.3.3.2 Key Country Dynamics
      • 7.3.3.3 Regulatory Framework
      • 7.3.3.4 Reimbursement Scenario
    • 7.3.4 Spain
      • 7.3.4.1 Spain Cancer Biopsy Market, 2018 - 2030 (USD Million)
      • 7.3.4.2 Key Country Dynamics
      • 7.3.4.3 Regulatory Framework
      • 7.3.4.4 Reimbursement Scenario
    • 7.3.5 France
      • 7.3.5.1 France Cancer Biopsy Market, 2018 - 2030 (USD Million)
      • 7.3.5.2 Key Country Dynamics
      • 7.3.5.3 Regulatory Framework
      • 7.3.5.4 Reimbursement Scenario
    • 7.3.6 Italy
      • 7.3.6.1 Italy Cancer Biopsy Market, 2018 - 2030 (USD Million)
      • 7.3.6.2 Key Country Dynamics
      • 7.3.6.3 Regulatory Framework
      • 7.3.6.4 Reimbursement Scenario
    • 7.3.7 Denmark
      • 7.3.7.1 Denmark Cancer Biopsy Market, 2018 - 2030 (USD Million)
      • 7.3.7.2 Key Country Dynamics
      • 7.3.7.3 Regulatory Framework
      • 7.3.7.4 Reimbursement Scenario
    • 7.3.8 Sweden
      • 7.3.8.1 Sweden Cancer Biopsy Market, 2018 - 2030 (USD Million)
      • 7.3.8.2 Key Country Dynamics
      • 7.3.8.3 Regulatory Framework
      • 7.3.8.4 Reimbursement Scenario
    • 7.3.9 Norway
      • 7.3.9.1 Norway Cancer Biopsy Market, 2018 - 2030 (USD Million)
      • 7.3.9.2 Key Country Dynamics
      • 7.3.9.3 Regulatory Framework
      • 7.3.9.4 Reimbursement Scenario
  • 7.4 Asia Pacific
    • 7.4.1 Asia-Pacific Cancer Biopsy Market, 2018 - 2030 (USD Million)
    • 7.4.2 Japan
      • 7.4.2.1 Japan Cancer Biopsy Market, 2018 - 2030 (USD Million)
      • 7.4.2.2 Key Country Dynamics
      • 7.4.2.3 Regulatory Framework
      • 7.4.2.4 Reimbursement Scenario
    • 7.4.3 China
      • 7.4.3.1 China Cancer Biopsy Market, 2018 - 2030 (USD Million)
      • 7.4.3.2 Key Country Dynamics
      • 7.4.3.3 Regulatory Framework
      • 7.4.3.4 Reimbursement Scenario
    • 7.4.4 India
      • 7.4.4.1 India Cancer Biopsy Market, 2018 - 2030 (USD Million)
      • 7.4.4.2 Key Country Dynamics
      • 7.4.4.3 Regulatory Framework
      • 7.4.4.4 Reimbursement Scenario
    • 7.4.5 South Korea
      • 7.4.5.1 South Korea Cancer Biopsy Market, 2018 - 2030 (USD Million)
      • 7.4.5.2 Key Country Dynamics
      • 7.4.5.3 Regulatory Framework
      • 7.4.5.4 Reimbursement Scenario
    • 7.4.6 Thailand
      • 7.4.6.1 Thailand Cancer Biopsy Market, 2018 - 2030 (USD Million)
      • 7.4.6.2 Key Country Dynamics
      • 7.4.6.3 Regulatory Framework
      • 7.4.6.4 Reimbursement Scenario
    • 7.4.7 Australia
      • 7.4.7.1 Australia Cancer Biopsy Market, 2018 - 2030 (USD Million)
      • 7.4.7.2 Key Country Dynamics
      • 7.4.7.3 Regulatory Framework
      • 7.4.7.4 Reimbursement Scenario
  • 7.5 Latin America
    • 7.5.1 Latin America Cancer Biopsy Market, 2018 - 2030 (USD Million)
    • 7.5.2 Brazil
      • 7.5.2.1 Brazil Cancer Biopsy Market, 2018 - 2030 (USD Million)
      • 7.5.2.2 Key Country Dynamics
      • 7.5.2.3 Regulatory Framework
      • 7.5.2.4 Reimbursement Scenario
    • 7.5.3 Mexico
      • 7.5.3.1 Mexico Cancer Biopsy Market, 2018 - 2030 (USD Million)
      • 7.5.3.2 Key Country Dynamics
      • 7.5.3.3 Regulatory Framework
      • 7.5.2.4 Reimbursement Scenario
    • 7.5.4 Argentina
      • 7.5.4.1 Argentina Cancer Biopsy Market, 2018 - 2030 (USD Million)
      • 7.5.4.2 Key Country Dynamics
      • 7.5.4.3 Regulatory Framework
      • 7.5.4.4 Reimbursement Scenario
  • 7.6 MEA
    • 7.6.1 MEA Cancer Biopsy Market, 2018 - 2030 (USD Million)
    • 7.6.2 South Africa
      • 7.6.2.1 South Africa Cancer Biopsy Market, 2018 - 2030 (USD Million)
      • 7.6.2.2 Key Country Dynamics
      • 7.6.2.3 Regulatory Framework
      • 7.6.2.4 Reimbursement Scenario
    • 7.6.3 Saudi Arabia
      • 7.6.3.1 Saudi Arabia Cancer Biopsy Market, 2018 - 2030 (USD Million)
      • 7.6.3.2 Key Country Dynamics
      • 7.6.3.3 Regulatory Framework
      • 7.6.3.4 Reimbursement Scenario
    • 7.6.4 Uae
      • 7.6.4.1 Uae Cancer Biopsy Market, 2018 - 2030 (USD Million)
      • 7.6.4.2 Key Country Dynamics
      • 7.6.4.3 Regulatory Framework
      • 7.6.2.4 Reimbursement Scenario
    • 7.6.5 Kuwait
      • 7.6.5.1 Kuwait Cancer Biopsy Market, 2018 - 2030 (USD MILLION)
      • 7.6.5.2 Key Country Dynamics
      • 7.6.5.3 Regulatory Framework
      • 7.6.5.4 Reimbursement Scenario

Chapter 8 Cancer Biopsy Market: Competitive Landscape

  • 8.1 Company Categorization
  • 8.2 Strategy Mapping
    • 8.2.1 New product launch
    • 8.2.2 Partnerships
    • 8.2.3 Acquisition
    • 8.2.4 Collaboration
    • 8.2.5 Funding
  • 8.3 Company Market Share Analysis, 2022
  • 8.4 Company Profiles
    • 8.4.1 QIAGEN
      • 8.4.1.1 Company overview
      • 8.4.1.2 Financial performance
      • 8.4.1.3 Product benchmarking
      • 8.4.1.4 Strategic initiatives
    • 8.4.2 ILLUMINA, INC.
      • 8.4.2.1 Company overview
      • 8.4.2.2 Financial performance
      • 8.4.2.3 Product benchmarking
      • 8.4.2.4 Strategic initiatives
    • 8.4.3 ANGLE PLC
      • 8.4.3.1 Company overview
      • 8.4.3.2 Financial performance
      • 8.4.3.3 Product benchmarking
      • 8.4.3.4 Strategic initiatives
    • 8.4.4 BD (BECTON, DICKINSON AND COMPANY)
      • 8.4.4.1 Company overview
      • 8.4.4.2 Financial performance
      • 8.4.4.3 Product benchmarking
      • 8.4.4.4 Strategic initiatives
    • 8.4.5 MYRIAD GENETICS
      • 8.4.5.1 Company overview
      • 8.4.5.1.1 Counsyl, Inc.
      • 8.4.5.2 Financial performance
      • 8.4.5.3 Product benchmarking
      • 8.4.5.4 Strategic initiatives
    • 8.4.6 HOLOGIC, INC.
      • 8.4.6.1 Company overview
      • 8.4.6.2 Financial performance
      • 8.4.6.3 Product benchmarking
    • 8.4.7 BIOCEPT, INC.
      • 8.4.7.1 Company overview
      • 8.4.7.2 Financial performance
      • 8.4.7.3 Product benchmarking
      • 8.4.7.4 Strategic initiatives
    • 8.4.8 THERMO FISHER SCIENTIFIC, INC.
      • 8.4.8.1 Company overview
      • 8.4.8.2 Financial performance
      • 8.4.8.3 Product benchmarking
      • 8.4.8.4 Strategic initiatives
    • 9.4.9 DANAHER
      • 8.4.9.1 Company overview
      • 8.4.9.2 Beckman Coulter, Inc
      • 8.4.9.3 Radiometer Medical ApS
      • 8.4.9.4 HemoCue AB
      • 8.4.9.5 Financial performance
      • 8.4.9.6 Product benchmarking
    • 8.4.10 F. HOFFMANN-LA ROCHE LTD.
      • 8.4.10.1 Company overview
      • 8.4.10.2 FOUNDATION MEDICINE, INC.
      • 8.4.10.3 Financial performance
      • 8.4.10.4 Product benchmarking
    • 8.4.11 LUCENCE DIAGNOSTICS PTE. LTD.
      • 8.4.11.1 Company overview
      • 8.4.11.2 Financial performance
      • 8.4.11.3 Product benchmarking
      • 8.4.11.4 Strategic initiatives
    • 8.4.12 GRAIL, INC.
      • 8.4.12.1 Company overview
      • 8.4.12.2 Financial performance
      • 8.4.12.3 Product benchmarking
      • 8.4.12.4 Strategic initiatives
    • 8.4.13 GUARDANT HEALTH
      • 8.4.13.1 Company overview
      • 8.4.13.2 Financial performance
      • 8.4.13.3 Product benchmarking
      • 8.4.13.4 Strategic initiatives
    • 8.4.14 EXACT SCIENCES CORPORATION
      • 8.4.14.1 Company overview
      • 8.4.14.2 Financial performance
      • 8.4.14.3 Product benchmarking
      • 8.4.14.4 Strategic initiatives
    • 8.4.15 FREENOME HOLDINGS, INC.
      • 8.4.15.1 Company overview
      • 8.4.15.2 Financial performance
      • 8.4.15.3 Product benchmarking
      • 8.4.15.4 Strategic initiatives
    • 8.4.16 BIODESIX (INTEGRATED DIAGNOSTICS)
      • 8.4.16.1 Company overview
      • 8.4.16.2 Financial performance
      • 8.4.16.3 Product benchmarking
      • 8.4.16.4 Strategic initiatives
    • 8.4.17 ONCIMMUNE
      • 8.4.17.1 Company overview
      • 8.4.17.2 Financial performance
      • 8.4.17.3 Product benchmarking
      • 8.4.17.4 Strategic initiatives
    • 8.4.18 EPIGENOMICS AG.
      • 8.4.18.1 Company overview
      • 8.4.18.2 Financial performance
      • 8.4.18.3 Product benchmarking
      • 8.4.18.4 Strategic initiatives
    • 8.4.19 HELIOHEALTH (LABORATORY FOR ADVANCED MEDICINE)
      • 8.4.19.1 Company overview
      • 8.4.19.2 Financial performance
      • 8.4.19.3 Product benchmarking
      • 8.4.19.4 Strategic initiatives
    • 8.4.20 GENESYSTEMS, INC. (GENESYS BIOLABS)
      • 8.4.20.1 Company overview
      • 8.4.20.2 Financial performance
      • 8.4.20.3 Product benchmarking
      • 8.4.20.4 Strategic initiatives
    • 8.4.21 CHRONIX BIOMEDICAL, INC.
      • 8.4.21.1 Company overview
      • 8.4.21.2 Financial performance
      • 8.4.21.3 Product benchmarking
      • 8.4.21.4 Strategic initiatives
    • 8.4.22 PERSONAL GENOME DIAGNOSTICS INC.
      • 8.4.22.1 Company overview
      • 8.4.22.2 Financial performance
      • 8.4.22.3 Product benchmarking
      • 8.4.22.4 Strategic initiatives
    • 8.4.23 NATERA, INC.
      • 8.4.23.1 Company overview
      • 8.4.23.2 Financial performance
      • 8.4.23.3 Product benchmarking
      • 8.4.23.4 Strategic initiatives
    • 8.4.24 PERSONALIS INC.
      • 8.4.16.1 Company overview
      • 8.4.24.2 Financial performance
      • 8.4.24.3 Product benchmarking
      • 8.4.24.4 Strategic initiatives

Chapter 9 KOL Recommendations/Analyst Perspective

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviation
  • Table 3 North America cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 4 North America cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 5 North America cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 6 U.S. cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 7 U.S. cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 8 U.S. cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 9 Canada cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 10 Canada cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 11 Canada cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 12 Europe cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 13 Europe cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 14 Europe cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 15 Germany cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 16 Germany cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 17 Germany cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 18 UK cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 19 UK cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 20 UK cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 21 France cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 22 France cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 23 France cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 24 Spain cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 25 Spain cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 26 Spain cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 27 Italy cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 28 Italy cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 29 Italy cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 30 Denmark cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 31 Denmark cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 32 Denmark cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 33 Sweden cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 34 Sweden cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 35 Sweden cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 36 Norway cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 37 Norway cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 38 Norway cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 39 Asia Pacific cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 42 Japan cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 43 Japan cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 44 Japan cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 45 China cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 46 China cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 47 China cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 48 India cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 49 India cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 50 India cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 51 South Korea cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 52 South Korea cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 53 South Korea cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 54 Thailand cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 55 Thailand cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 56 Thailand cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 57 Australia cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 58 Australia cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 59 Australia cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 60 Latin America cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 61 Latin America cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 62 Latin America cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 63 Brazil cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 64 Brazil cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 65 Brazil cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 66 Mexico cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 67 Mexico cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 68 Mexico cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 69 Argentina cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 70 Argentina cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 71 Argentina cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 72 MEA cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 73 MEA cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 74 MEA cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 75 South Africa cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 76 South Africa cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 77 South Africa cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 78 Saudi Arabia cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 79 Saudi Arabia cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 80 Saudi Arabia cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 81 UAE cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 82 UAE cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 83 UAE cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 84 Kuwait cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 85 Kuwait cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 86 Kuwait cancer biopsy market, by application, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Cancer biopsy market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Market snapshot
  • Fig. 10 Segment snapshot
  • Fig. 11 Segment snapshot
  • Fig. 12 Competitive landscape
  • Fig. 13 Cancer Biopsy Market Value, 2022 (USD Billion)
  • Fig. 14 Cancer Biopsy - Industry value chain analysis
  • Fig. 15 Cancer biopsy market dynamics
  • Fig. 16 Cancer biopsy market: PORTER's analysis
  • Fig. 17 Cancer biopsy market: PESTEL analysis
  • Fig. 18 Cancer biopsy market: By application: Key takeaways
  • Fig. 19 Cancer biopsy market, by application: Market share, 2022 & 2030
  • Fig. 20 Genetic disorders market, 2018 - 2030 (USD Million)
  • Fig. 21 Oncology market, 2018 - 2030 (USD Million)
  • Fig. 22 Personalized medicine market, 2018 - 2030 (USD Million)
  • Fig. 23 Other application market, 2018 - 2030 (USD Million)
  • Fig. 24 Cancer biopsy market: By product: Key takeaways
  • Fig. 25 Cancer biopsy market, by product: Market share, 2022 & 2030
  • Fig. 26 Instruments market, 2018 - 2030 (USD Million)
  • Fig. 27 Kits and consumables market, 2018 - 2030 (USD Million)
  • Fig. 28 Services market, 2018 - 2030 (USD Million)
  • Fig. 29 Cancer biopsy market: By type: Key takeaways
  • Fig. 30 Cancer biopsy market, by type: Market share, 2022 & 2030
  • Fig. 31 Tissue biopsies market, 2018 - 2030 (USD Million)
  • Fig. 32 Needle biopsies market, 2018 - 2030 (USD Million)
  • Fig. 33 Fine needle aspiration (FNA) market, 2018 - 2030 (USD Million)
  • Fig. 34 Core needle biopsy (CNB) market, 2018 - 2030 (USD Million)
  • Fig. 35 Surgical biopsies market, 2018 - 2030 (USD Million)
  • Fig. 36 Liquid biopsies market, 2018 - 2030 (USD Million)
  • Fig. 37 Others market, 2018 - 2030 (USD Million)
  • Fig. 38 Cancer biopsy market: By application: Key takeaways
  • Fig. 39 Cancer biopsy market, by application: Market share, 2022 & 2030
  • Fig. 40 Breast cancer market, 2018 - 2030 (USD Million)
  • Fig. 41 Colorectal cancer market, 2018 - 2030 (USD Million)
  • Fig. 42 Cervical cancers market, 2018 - 2030 (USD Million)
  • Fig. 43 Lung cancers market, 2018 - 2030 (USD Million)
  • Fig. 44 Prostate cancer market, 2018 - 2030 (USD Million)
  • Fig. 45 Skin cancer market, 2018 - 2030 (USD Million)
  • Fig. 46 Blood cancers market, 2018 - 2030 (USD Million)
  • Fig. 47 Kidney cancers market, 2018 - 2030 (USD Million)
  • Fig. 48 Liver cancer market, 2018 - 2030 (USD Million)
  • Fig. 49 Pancreatic cancers market, 2018 - 2030 (USD Million)
  • Fig. 50 Ovarian cancers market, 2018 - 2030 (USD Million)
  • Fig. 51 Others market, 2018 - 2030 (USD Million)
  • Fig. 52 Cancer biopsy market revenue, by region, 2022 & 2030, (USD Million)
  • Fig. 53 Regional marketplace: Key takeaways
  • Fig. 54 Regional marketplace: Key takeaways
  • Fig. 55 North America: SWOT analysis
  • Fig. 56 North America cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Key country dynamics
  • Fig. 58 Reimbursement procurement process
  • Fig. 59 U.S. cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Key country dynamics
  • Fig. 61 Canada cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Europe: SWOT analysis
  • Fig. 63 Europe cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Key country dynamics
  • Fig. 65 Germany cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 Key country dynamics
  • Fig. 67 UK cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Key country dynamics
  • Fig. 69 France color-correcting classes market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Key country dynamics
  • Fig. 71 Italy cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 Key country dynamics
  • Fig. 73 Spain cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 Key country dynamics
  • Fig. 75 Denmark cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Key country dynamics
  • Fig. 77 Sweden cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 Key country dynamics
  • Fig. 79 Norway cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 80 Asia Pacific: SWOT analysis
  • Fig. 81 Asia Pacific cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 82 Key country dynamics
  • Fig. 83 Reimbursement procurement process
  • Fig. 84 Japan cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 85 Key country dynamics
  • Fig. 86 China cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 87 Key country dynamics
  • Fig. 88 India cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 89 Key country dynamics
  • Fig. 90 Australia cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 91 Key country dynamics
  • Fig. 92 South Korea cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 93 Key country dynamics
  • Fig. 94 Thailand cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 95 Latin America: SWOT analysis
  • Fig. 96 Latin America cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 97 Key country dynamics
  • Fig. 98 Brazil cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 99 Key country dynamics
  • Fig. 100 Mexico cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 101 Key country dynamics
  • Fig. 102 Argentina cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 103 MEA: SWOT analysis
  • Fig. 104 Middle East & Africa cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 105 Key country dynamics
  • Fig. 106 South Africa cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 107 Key country dynamics
  • Fig. 108 Saudi Arabia cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 109 Key country dynamics
  • Fig. 110 UAE cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 111 Key country dynamics
  • Fig. 112 Kuwait cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 113 Key company categorization
  • Fig. 114 Company market position analysis
  • Fig. 115 Strategic framework